Histologic grade does not predict prognosis in optimally treated, advanced‐stage nodular sclerosing Hodgkin's disease

Forty‐two patients with advanced‐stage nodular sclerosing Hodgkin's disease (NSHD) were treated uniformly with combination chemotherapy and radiation therapy at the University of Nebraska Medical Center between 1982 and 1987. The cases were subclassified into low‐grade (13 cases) and high‐grade...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1992-01, Vol.69 (1), p.228-232
Main Authors: Masih, Aneal S., Weisenburger, Dennis D., Vose, Julie M., Bast, Martin A., Armitage, James O.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant
Female
Follow-Up Studies
Hodgkin Disease - drug therapy
Hodgkin Disease - pathology
Hodgkin Disease - radiotherapy
Humans
Male
Middle Aged
Neoplasm Staging
Prognosis
Remission Induction
Sclerosis
Survival Analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty‐two patients with advanced‐stage nodular sclerosing Hodgkin's disease (NSHD) were treated uniformly with combination chemotherapy and radiation therapy at the University of Nebraska Medical Center between 1982 and 1987. The cases were subclassified into low‐grade (13 cases) and high‐grade (29 cases) categories using the British National Lymphoma Investigation (BNLI) histologic criteria. After a median follow‐up interval of 48 months, no significant differences with regard to the complete remission rate (100% versus 90%), remission durability (85% versus 96%), or predicted 4‐year actuarial survival (92% versus 86%) were observed between the two groups, respectively. It was concluded that the BNLI grading scheme for NSHD does not predict the clinical outcome of patients with advanced‐stage NSHD who receive optimal therapy.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19920101)69:1<228::AID-CNCR2820690137>3.0.CO;2-9